Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones

被引:54
|
作者
Wispelwey, B [1 ]
机构
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
关键词
D O I
10.1086/428053
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This review summarizes key data illustrating the clinical importance of pharmacodynamics, particularly among the fluoroquinolone family of antibacterials. Antibacterials are often divided into 2 groups - either time-dependent or concentration-dependent agents - on the basis of their mechanism of killing. Fluoroquinolones are concentration-dependent agents, and the parameter that correlates most closely with clinical and/or bacteriological success is the ratio of the area under plasma concentration curve (AUC) to the minimum inhibitory concentration ( MIC). The AUC: MIC threshold may vary by organism. For example, a ratio of at least 30 is often cited as optimal to achieve success against Streptococcus pneumoniae, whereas higher ratios ( > 100) are considered to be optimal for the treatment of infections due to gram-negative bacilli. Data are cited to suggest that the minimum ratio necessary to prevent the selection of resistant mutants may, in fact, be somewhat higher. Maximizing the AUC: MIC through the use of potent therapy may offer an opportunity to limit the development of resistance to fluoroquinolones.
引用
收藏
页码:S127 / S135
页数:9
相关论文
共 50 条
  • [21] Pharmacodynamics of fluoroquinolones
    Lode, H
    Borner, K
    Koeppe, P
    CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) : 33 - 39
  • [22] Pharmacokinetics and pharmacodynamics of newer fluoroquinolones in patients with lower respiratory tract infections
    Kontou, Paschalina
    Chatzika, Kalliopi
    Manika, Katerina
    Pitsiou, Georgia
    Sionidou, Maria
    Kioumis, Ioannis
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [23] Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
    Wasmann, Roeland E.
    Muilwijk, Eline W.
    Burger, David M.
    Verweij, Paul E.
    Knibbe, Catherijne A.
    Bruggemann, Roger J.
    CLINICAL PHARMACOKINETICS, 2018, 57 (03) : 267 - 286
  • [24] Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
    Puszkiel, Alicja
    Noe, Gaelle
    Bellesoeur, Audrey
    Kramkimel, Nora
    Paludetto, Marie-Noelle
    Thomas-Schoemann, Audrey
    Vidal, Michel
    Goldwasser, Francois
    Chatelut, Etienne
    Blanchet, Benoit
    CLINICAL PHARMACOKINETICS, 2019, 58 (04) : 451 - 467
  • [25] Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren
    Sujata Vaidyanathan
    Venkateswar Jarugula
    Hans Armin Dieterich
    Dan Howard
    William P. Dole
    Clinical Pharmacokinetics, 2008, 47 : 515 - 531
  • [26] Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin
    Kyle C. Molina
    Matthew A. Miller
    Scott W. Mueller
    Edward T. Van Matre
    Martin Krsak
    Tyree H. Kiser
    Clinical Pharmacokinetics, 2022, 61 : 363 - 374
  • [27] Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
    Thomas Müller
    Paul Foley
    Clinical Pharmacokinetics, 2017, 56 : 251 - 261
  • [28] Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin
    Jennifer Shiu
    Grace Ting
    Tony KL Kiang
    European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44 : 305 - 317
  • [29] Clinical Pharmacokinetics and Pharmacodynamics of Isepamicin
    Michel Tod
    Christophe Padoin
    Olivier Petitjean
    Clinical Pharmacokinetics, 2000, 38 : 205 - 223
  • [30] Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
    Mingxiang Liao
    Jeri Beltman
    Heidi Giordano
    Thomas C. Harding
    Lara Maloney
    Andrew D. Simmons
    Jim J. Xiao
    Clinical Pharmacokinetics, 2022, 61 : 1477 - 1493